Applied Genetic Tech files IND for gene therapy candidate to treat certain type of retinitis pigmentosa

|About: Applied Genetic Techno... (AGTC)|By:, SA News Editor

Applied Genetic Technologies (AGTC -1%) files an Investigational New Drug (IND) application with the FDA seeking approval to launch a Phase 1/2 clinical trial assessing its RPGR gene therapy candidate for the treatment of X-linked retinitis pigmentosa (XLRP), an inherited condition that leads to vision loss. The study will be initiated in the coming months.

Subscribe for full text news in your inbox